BIM
IMUC

BlackRock Investment Management’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

BlackRock Investment Management’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-381
Closed -$7K – 4330
2015
Q1 		$7K Buy
381
+128
+51% +$3.21K ﹤0.01% 3799
2014
Q4 		$7K Hold
253
– – ﹤0.01% 3826
2014
Q3 		$9K Buy
253
+27
+12% +$1.04K ﹤0.01% 3740
2014
Q2 		$10K Buy
+226
New +$10.9K ﹤0.01% 3658

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Investment Management's IMUC Position: Q2 2015 in Review

BlackRock Investment Management sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q2 2015, closing a stake of 381 shares — an estimated $7K sold.

BlackRock Investment Management first reported a position in IMUC in Q2 2014 and held it in 4 quarters. The position peaked at $10K in Q2 2014. 31 funds tracked by Wall St. Rank hold IMUC as of Q2 2015.

  • BlackRock Investment Management reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q2 2015 after selling out during the quarter.
  • BlackRock Investment Management sold 381 ImmunoCellular Therapeutics, Ltd. shares in Q2 2015, an estimated $7K.
  • BlackRock Investment Management first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2014 and held it in 4 quarters.
  • BlackRock Investment Management's ImmunoCellular Therapeutics, Ltd. position peaked at $10K in Q2 2014.
  • 31 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q2 2015.

Based on BlackRock Investment Management's 13F filing for Q2 2015, filed 7 Aug 2015.